Novel androgen receptor inhibitor cream ‘appears effective’ for acne

But comparisons with existing acne treatments are needed, an expert commentator says
Reuters Health Staff writer

Topical clascoterone cream, an androgen receptor inhibitor, appears safe and effective for individuals with acne, researchers say.

The cream was tested in two phase 3 double-blind trials run by the manufacturer.

More than 1400 people, each with 30-75 inflammatory lesions and 30-100 noninflammatory lesions, were randomised to treatment with clascoterone cream (1%) or a vehicle cream, applying approximately 1g to the whole face twice daily for 12 weeks.

The median age of participants was 18, 62% were female, with the mean number of inflammatory and noninflammatory lesions at baseline being 42.4 and 61.5 respectively, the authors reported in JAMA Dermatology.